Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DURECT Corporation
‘Clinically Meaningful Outcomes’ Data Urged For Long-Acting, Local Anesthetic Drug Products
Although a new FDA guidance recommends difference in pain scores as the primary efficacy endpoint for evaluation of postoperative analgesic effect, data on outcomes such as reduction in hospitalization and deaths from opioid abuse would be valuable and could provide a basis for inclusion in labeling; guidance is part of broader agency effort to reduce opioid use.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
News We’re Watching – 13 January
This new Medtech Insight feature compiles news briefs on a range of regulatory and legal happenings. This week: Guidance documents on photobiomodulation devices and COVID-19 submissions; legal settlements for Abbott and Jet Medical; and a new partnership for Pear Therapeutics.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.